<DOC>
	<DOCNO>NCT02726542</DOCNO>
	<brief_summary>Fatty liver disease increase problem overweight obese adolescent . The purpose study test effect growth hormone liver fat obese adolescent increase liver fat .</brief_summary>
	<brief_title>Augmenting Growth Hormone Ameliorate Nonalcoholic Fatty Liver Disease Adolescents</brief_title>
	<detailed_description>Non-alcoholic fatty liver disease ( NAFLD ) significant health problem obese adolescent . Obese child adolescent significant reduction growth hormone secretion , hypothesize augment growth hormone population decrease liver fat . Growth hormone inhibit hepatic de novo lipogenesis , important source hepatic lipid . Patients pituitary GH deficiency high prevalence NAFLD non-alcoholic steatohepatitis ( NASH ) general population , replacement GH individual reduce sign liver damage . The purpose study test hypothesis growth hormone treatment decrease liver fat quantity adolescent begin trial 5 % liver fat measure magnetic resonance spectroscopy .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion criterion : 1 . Males Females age 1825yo 2 . BMI ≥95th percentile and/or ≥30kg/m^2 3 . Hepatic fat ≥5 % hydrogen magnetic resonance spectroscopy ( 1HMRS ) 4 . IGF1 standard deviation score ( SDS ) ≤ 0.5 Exclusion criterion : 1 . Alcohol consumption &gt; 14 drink per week ( Females ) &gt; 21 drink per week ( Males ) 2 . Use insulin oral antidiabetic medication , hemoglobin A1c ( HbA1c ) &gt; 7 % fast glucose ≥126mg/dL 3 . Use corticosteroid , gonadal steroid , methotrexate ≤ 3 month prior baseline visit 4 . Known diagnosis alpha1 antitrypsin deficiency , Wilson 's disease , hemochromatosis , autoimmune hepatitis 5. hemoglobin &lt; 11.0 g/dL weight &lt; 50kg 6. aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5x upper limit normal ( ULN ) , total bilirubin &gt; ULN , positive hepatitis B surface antigen ( sAg ) , positive hepatitis C antibody 7 . Routine magnetic resonance imaging ( MRI ) exclusion criterion ( include weight &gt; 450 pound ) 8 . Use weightloss medication previous weight loss surgery 9 . Pregnant breastfeeding , , sexuallyactive female , unwillingness use appropriate form contraception study 10 . Known cirrhosis clinical evidence cirrhosis portal hypertension image exam 11 . Use growth hormone ( GH ) growth hormone release hormone within past 1 year 12 . Change lipid lower antihypertensive medication within 3 month screen 13 . Change vitamin E ursodiol &lt; 6 month screen ; subject stable dos Vitamin E and/or Ursodiol ≥6 month eligible . 14 . History malignancy active malignancy 15 . History hypopituitarism , head irradiation condition chronic illness know affect GH axis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>obesity</keyword>
	<keyword>adolescence</keyword>
	<keyword>fatty liver</keyword>
	<keyword>growth hormone</keyword>
</DOC>